UAB Phase I Clinical Trials Program – Phase I “CATCH ALL” Trials

**SOLID TUMORS**

- **p53 WT only**
- **OVARIAN NHL/HL NSCLC SCCHN GBM MELANOMA CRC**

**SOLID TUMOR LYMPHOMA**

1. **UAB1469 ALRN6924 MDM2/MDX INHIBITOR**
   - A. IV ON D1, 8, 15 (q 28d)
   - B. IV ON D1, 4, 11 (q 21d)

**2. UAB1506 INCB24360 IDO INHIBITOR + Anti PD1**
   - Nivolumab=IV q 2wks on Days 1, 15, 29, 43 of each 8-week cycle INCBO24360=PO BID
   - SPECIAL INSTRUCTIONS: The INCBO24360 is given PO BID (1 week on/off is an option depending on which cohort subject is enrolled in).

**3. UAB 1507 INCB52793 JAK-1 INHIBITOR**
   - PO QD X 2wks on and 1 wk off (CYCLE 21 DAYS)
   - SPECIAL INSTRUCTIONS: THE INCBO52793 MUST BE AVAILABLE FROM THE PREVIOUS 2 YEARS OR SUBJECT MUST UNDERGO A BX FOR FGFR TESTING

**4. UAB 1508 INCB054828 FGFR INHIBITOR**
   - CLINIC VISITS D1, 2 8, 15 OF CYCLE 1;
   - SUBSEQUENT VISITS D1, 8 & 15
   - SPECIAL INSTRUCTIONS:

**5. UAB 1540 MGCD516 RTK INHIBITOR**
   - PO
   - SPECIAL INSTRUCTIONS:

**6. UAB1559 H8B-MC-JBEF TGF-Beta INHIBITOR + Anti PD1**
   - PO 14 days on/off
   - SPECIAL INSTRUCTIONS: 4 cohorts – 3+3 design; n = 3 to 15 in each cohort; NSCLC/HCC/GBM cohort in Phase II

**HEMATOLOGIC MALIGNANCY**

**SPECIAL INSTRUCTIONS:**

FOR REFERRALS OR QUESTIONS CALL (24/7): 205-996-HOPE (996-4673) OR EMAIL: phase1referral@uab.edu

Version-9-18-2015